Virginia Commonwealth University · BiologyThe Cancer Resilience Lab
Senthil Kumar Radhakrishnan · Richmond, Virginia
Research Focus
Dr. Senthil Kumar Radhakrishnan's lab focuses on enhancing the effectiveness of cancer therapies, particularly through the study of proteases. They are specifically investigating the DDI2 protease, which helps cancer cells survive during treatments with proteasome inhibitors used in multiple myeloma. By identifying small molecule inhibitors of DDI2, the lab aims to improve the survival rates and treatment outcomes for cancer patients.
proteasome inhibitorscancer treatmentDDI2 proteasedrug discoverybreast cancer
Research Aims
3AIM 01Identify small molecule inhibitors that bind to the DDI2 protease.
AIM 02Confirm and profile hits from high-throughput screens using secondary assays.
AIM 03Validate the mechanism of action of DDI2 inhibitors and assess their impact on cancer cell apoptosis.
Skills the Lab Values
high-throughput screeningprotein purificationcell culturebiophysical assaysapoptosis assays